治疗性抗体先导化合物发现
查找筛选最具潜力的
候选先导化合物所需的工具。
治疗性抗体先导化合物发现涉及靶向疗法抗体候选物的筛选。确定特定靶标后，使用靶分子作为抗原产生抗体。可通过杂交瘤技术、B 细胞克隆和噬菌体展示等方法生成抗体。然后纯化抗体，根据结合抗原的能力进行筛选。对筛选的抗体进行进一步特征鉴定，确定其特异性、亲和力、稳定性和药代动力学特性。从单克隆抗体生成到分离、筛选和先导化合物优化过程，我们提供了无数的平台和试剂，帮助您开展先导化合物发现过程。
单克隆抗体先导化合物发现
时间和金钱
单克隆抗体生产是整个发现过程最费时费力的环节之一。B细胞克隆和噬菌体展示领域的最新进展彻底改变了抗体库生成，降低了成本并加快了先导化合物发现进程。
相关类别
我们提供了广泛的蛋白质纯化色谱工具。
用于基因编辑、克隆、PCR，以及蛋白表达与检测的工具。
人类原代细胞、正常和疾病状态的PBMC和免疫细胞。
用于高级细胞培养的人类iPSC分化类器官和患者来源类器官。
促进自然、多维生长，以获得更相关的体外模型。
水凝胶、类器官、ULA板、微孔板和其他培养器皿。
相关文章
- Hybridoma Fusion Partner Cell Lines
Choose from dozens of options to find the optimal fusion partner and increase the efficiency of hybridoma growth and antibody synthesis.
- Cryopreserved PBMCs Retain Function and Phenotype
Frozen peripheral blood mononuclear cells offer many advantages over fresh PBMCs, enabling researchers to plan their experiments ahead of time with ready-to-use cells that can be stored in the freezer until needed.
- Gastrointestinal Organoid Biobank
Patient derived organoids (PDOs) can be used as in vitro 3D cell models, preserving original tissue physiology and molecular pathology for clinical relevance.
- Lung Cancer Organoid Biobank
Lung patient derived organoids (PDOs) have been shown to be a reliable model for lung cancer studies, and can also predict patient clinical responses to therapeutics.
- A Highly Sensitive IFN-γ ELISpot Assay to Quantify Cellular Immune Responses to Previous Viral Infection
This study presents an example of a typical ELISpot assay for quantifying the number of pre-existing, antigen-reactive T cells from peripheral blood mononuclear cell (PBMC) samples obtained from donors previously infected with cytomegalovirus (CMV).
- The ELISpot Assay Enables Functional Analysis of Cellular Immunology
Recent improvements to the design of multiwell microplates, including use of membranes with reduced background fluorescence, have bolstered the widespread application of ELISpot assays.
相关视频
探索我们的产品和服务
如要继续阅读，请登录或创建帐户。
暂无帐户？